[Federal Register Volume 64, Number 173 (Wednesday, September 8, 1999)]
[Notices]
[Pages 48843-48844]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-23229]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 99D-2726]
Medical Devices; Draft Guidance on Labeling for Laboratory Tests;
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of the draft guidance entitled `` Draft Guidance on
Labeling for Laboratory Tests.'' This draft guidance is not final nor
is it in effect at this time. The draft guidance is intended to
identify the information that should be provided to FDA for labeling
the diagnostic performance of laboratory tests. FDA intends to
recognize two major categories of endpoints for assessing diagnostic
performance of new ``in vitro diagnostic'' assays.
DATES: Written comments concerning this draft guidance must be received
by December 7, 1999.
ADDRESSES: See the SUPPLEMENTARY INFORMATION section for information on
electronic access to the draft guidance. Submit written requests for
single copies on a 3.5'' diskette of the draft guidance entitled
``Draft Guidance on Labeling for Laboratory Tests'' to the Division of
Small Manufacturers Assistance (HFZ-220), Center for Devices and
Radiological Health, Food and Drug Administration, 1350 Piccard Dr.,
Rockville, MD 20850. Send two self-addressed adhesive labels to assist
that office in processing your request, or fax your request to 301-443-
8818.
Submit written comments on the draft guidance to the Dockets
Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Joseph L. Hackett, Center for Devices
and Radiological Health (HFZ-440), Food and Drug Administration, 2098
Gaither Rd., Rockville, MD 20850, 301-594-3084.
SUPPLEMENTARY INFORMATION:
I. Background
The labeling and evaluation of laboratory test performance should
compare a new product's test results to some appropriate and relevant
diagnostic benchmark that can be used to correlate results from a new
test with the clinical status or condition of individuals or patients
for whom the test is intended to be used. Determination of the clinical
status of patients whose specimens are used in an evaluation may be
based on laboratory and/or clinical endpoints. FDA recognizes two major
categories of endpoints for assessing performance of new laboratory
assays: (1) ``True'' diagnostic state (patient clinical status or
condition) or operational ``truth,'' and (2) laboratory equivalence
where the test is characterized in terms of a
[[Page 48844]]
comparison to a legally marketed predicate.
This draft guidance represents the agency's current thinking on
labeling of diagnostic performance for new laboratory tests. It does
not create or confer any rights for or on any person and does not
operate to bind FDA or the public. An alternative approach may be used
if such approach satisfies the applicable statute, regulations, or
both.
The agency has adopted good guidance practices (GGP's), which set
forth the agency's policies and procedures for the development,
issuance, and use of guidance documents (62 FR 8961, February 27,
1997). This draft guidance is issued as a Level 1 guidance consistent
with GGP's.
II. Electronic Access
In order to receive the ``Draft Guidance on Labeling for Laboratory
Tests'' via your fax machine, call the CDRH Facts-On-Demand system at
800-899-0381 or 301-827-0111 from a touch-tone telephone. At the first
voice prompt press 1 to access DSMA Facts, at second voice prompt press
2, and then enter the document number (1352) followed by the pound sign
(#). Then follow the remaining voice prompts to complete your request.
Persons interested in obtaining a copy of the draft guidance may
also do so using the World Wide Web (WWW). CDRH maintains an entry on
the WWW for easy access to information including text, graphics, and
files that may be downloaded to a personal computer with access to the
WWW. Updated on a regular basis, the CDRH home page includes the
``Draft Guidance on Labeling for Laboratory Tests,'' device safety
alerts, Federal Register reprints, information on premarket submissions
(including lists of approved applications and manufacturers'
addresses), small manufacturers' assistance, information on video
conferencing and electronic submissions, mammography matters, and other
device-oriented information. The CDRH home page may be accessed at
``http://www.fda.gov/cdrh''.
III. Comments
Interested persons may submit to the Dockets Management Branch
(address above) written comments regarding this draft guidance. Two
copies of any comments are to be submitted, except that individuals may
submit one copy. Comments should be identified with the docket number
found in brackets in the heading of this document. A copy of the draft
guidance and received comments are available for public examination in
the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through
Friday.
Dated: August 24, 1999.
Linda S. Kahan,
Deputy Director for Regulations Policy, Center for Devices and
Radiological Health.
[FR Doc. 99-23229 Filed 9-7-99; 8:45 am]
BILLING CODE 4160-01-F
